The decision follows phase 3 trial data showing the immunotherapy cut disease recurrence or death risk by 68% in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback